Comparison · NCT04425629-eae26900
Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV. Trial comparisons, record NCT04425629-eae26900. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04425629-eae26900
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0133 | 0.00842 | 0.0209 | wilson | |
| Risk in group 2 | 0.0462 | 0.0362 | 0.0588 | wilson | |
| Risk difference, group 1 minus group 2 | -0.033 | -0.0465 | -0.0204 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.287 | 0.171 | 0.483 | log | |
| Odds ratio, group 1 over group 2 | 0.278 | 0.163 | 0.472 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase 3 Cohort 1 (2.4g IV) >= 18 than on Phase 3 Cohort 1 (Placebo) >=18 | 30.3 | 21.5 | 49.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 3 Cohort 1 (2.4g IV) >= 18 | Phase 3 Cohort 1 (2.4g IV) | 18 | 1,355 | OG001 |
| Group 2 | Phase 3 Cohort 1 (Placebo) >=18 | Phase 3 Cohort 1 (Placebo) | 62 | 1,341 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV
- Description
- Phase 3 (Cohort 1)
- Time frame
- Through day 29
- Population
Participants that were ≥18 years old and not pregnant at randomization, and randomized on or before 17-Jan-2021 with detectable SARS-CoV-2 RNA by RT-qPCR in nasopharyngeal swabs at randomization and at least 1 risk factor for severe COVID-19 at baseline
Source ClinicalTrials.gov
Trial
- Title
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
- NCT number
- NCT04425629
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab combination therapy
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2023-12-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04425629?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04425629-eae26900